Biologics Market - Growth, Trends, COVID-19 Impact and Forecasts (2021 - 2026)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 120 Pages | 納期: 2~3営業日

価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.01円
出版日: 2021年03月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 120 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次


第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場概要

  • 現在の市場シナリオ
  • ファイブフォース分析

第6章 促進要因・抑制要因・機会・課題分析

  • 市場促進要因
  • 市場抑制要因
  • 機会
  • 主な課題

第7章 市場区分

  • 製品別
  • 適応別
  • 地域別

第8章 競合情勢

  • M&A分析
  • 契約・提携・パートナーシップ
  • 新製品発売

第9章 主要企業

  • Abbvie Inc.
  • Amgen
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Glaxosmithkline Plc.
  • Johnson & Johnson
  • Merck & Co
  • Novo Nordisk
  • Pfizer Inc.
  • Sanofi
  • その他

第10章 市場の将来見通し

Product Code: 56982

The biologics market is projected to register a CAGR of 9.06% during the forecast period, with a revenue of approximately USD 302.63 billion in 2020 and expected to reach USD 509.23 billion by 2026. The market is majorly driven by growing capital investment from the key market players, the rise in the burden of chronic diseases, loss of patent exclusivity of the leading biologic drugs, and growing demand and higher acceptability for innovative therapies.

With the growing COVID-19 burden, there is a huge demand for biologics during the pandemic, which might drive market growth. For instance, in May 2020, the National Research Council of Canada and China-based CanSino Biologics collaborated for the clinical development of the COVID-19 vaccine in Canada. The vaccine, known as Ad5-nCoV, is an adenovirus Type 5 vector-based vaccine currently in Phase II development in Wuhan, China. However, extensive research and development activities taking place on biologics for the treatment of COVID-19 are thus expected to drive the growth of the biologics market in near future.

According to World Health Organization statistics 2018, globally chronic diseases kill more than 41 million people each year. Cardiovascular diseases account for most chronic disease deaths, or 17.9 million people annually, followed by cancers (9 million), respiratory diseases (3.9 million), and diabetes (1.6 million). These four groups account for 80% of all chronic disorder deaths. Tobacco use, physical inactivity, alcohol consumption, and unhealthy diets create a risk of dying from non-communicable diseases.​ Also, the rising geriatric population is much susceptible to chronic diseases that help in increasing the biologics demand.

The biologic drugs are used in the treatment of major chronic diseases, notably cancer and autoimmune diseases, has enabled big pharmaceutical companies, like Eli Lilly and Company, Bristol-Myers Squibb, Novartis, AstraZeneca, and GlaxoSmithKline (GSK), to invest in these products. In 2019 three biological drugs were approved by the United States Food and Drug Administration (FDA), one of which is an anticoagulant solution by Griffons.

There are also increasing investments that have helped in driving the overall market growth. As Novartis AG has seen to invest around USD 700 million in its biologics facility in Singapore, and Bristol-Myers Squibb invested nearly USD 900 million in an Irish large-scale biologics facility that is anticipated to be completed by 2019.

Furthermore, increasing demand for biologics proves efficient in treating rheumatoid arthritis and Crohn's disease boosting the market even further.

Key Market Trends

Cancer Diseases Segment is Expected to Dominate the Application Segment Over the Forecast Period

The cancer burden is found increasing, and cancer therapies must be modified according to regional and national priorities. The goal of biological therapy for cancer is to induce the immune system to recognize and kill cancer cells.

The COVID-19 pandemic has found to disrupted cancer care, including delaying diagnoses and treatment and also halting the clinical trials. Furthermore, the healthcare systems are rapidly reorganizing cancer services to ensure that patients continue to receive essential care while minimizing exposure to SARS-CoV-2 infection. This has shown a slight negative impact but post-pandemic the situation is expected to get stabilized.

According to the Globocan Report 2020, globally there are 19,292,789 new cancer cases that have been reported and 9,958,133 are reported cancer deaths. The majorly affected cancer is breast cancer, lung cancer, colorectum cancer, and prostate cancer. Biological therapy is thus for cancer is used in the treatment of many types of cancer to prevent or slow tumour growth and to prevent the spread of cancer. Biological therapy often causes fewer toxic side effects than other cancer treatments. The goal of biological therapy for cancer is to induce the immune system to recognize and kill cancer cells.

Market players are also continuously focusing on the development of novel biologic therapeutics for the treatment of cancer and investing in research and development activities. For instance, in August 2019, Dr Reddy's Laboratories had launched its bevacizumab 'similar biologic', Versavo (DRZ_BZ) in India. Bevacizumab is a humanized monoclonal antibody used to treat various cancer, including colorectal, lung, breast, glioblastoma, kidney, and ovarian. Hence all these aforementioned factors have helped in the growth of the segment of biologics for cancer treatment.

North America Holds the Largest Market Share and is Believed to Follow the Same Trend over the Forecast Period

The North American healthcare biologics market has dominated the global market and is estimated to show a similar trend during the forecast period. The primary factors driving the overall is the increasing incidences of chronic diseases, the presence of well-established pharmaceutical companies, and an increase in the number of biotech companies.

With the rising COVID-19 pandemic, there are US-based companies that are racing to develop vaccines against the COVID-19. For instance, in March 2020, a Phase 1 clinical trial began at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle, to evaluate an investigational vaccine designed to protect against COVID-19. The vaccine is being developed by NIAID scientists and their collaborators at the biotechnology company Moderna, Inc.

According to the estimates of the American Cancer Society, in 2018, an estimated 1,735,350 new cancer cases were diagnosed, and 609,640 people succumbed to cancer in the United States. The most common cancer in the United States is breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer.

In August 2020, Biocon Biologics India, a fully integrated biosimilars company and a subsidiary of Biocon Ltd, and Mylan N.V. has announced the US launch of Semglee (insulin glargine injection). Hence all these factors are found boosting the overall market growth in the US.

Competitive Landscape

The biologics market is moderately competitive and consists of several major players. The companies are implementing certain strategic initiatives, such as a merger, new product launch, acquisition, and partnerships that help them in strengthening their market position. These companies have made huge capital investments in the research and development of biologics as the cost of biologics is quite high. Furthermore, the companies are either acquiring or merging with other companies, for significant deals. For instance, Shire acquired Baxalta to create a biologics-based product for the treatment of rare diseases and other specialized disorders. Pfizer bought Medivation mainly due to the prostate cancer drug Xtandi.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Capital Investment from Key Market Players
    • 4.2.2 Rise in the Prevalence of Chronic Diseases
    • 4.2.3 Loss of Patent Exclusivity of the Leading Biologic Drugs
    • 4.2.4 Growing Demand and Higher Acceptability for Innovative Therapies
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Process and Initial High Capital Investment
    • 4.3.2 Rising Control and Cost for Accessing Biologics
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Product
    • 5.1.1 Monoclonal Antibodies
    • 5.1.2 Vaccines
    • 5.1.3 Recombinant Hormones/Proteins
    • 5.1.4 Cellular Based Biologics
    • 5.1.5 Gene Based Biologics
    • 5.1.6 Other Products
  • 5.2 By Application
    • 5.2.1 Cancer Diseases
    • 5.2.2 Infectious Diseases
    • 5.2.3 Autoimmune Diseases
    • 5.2.4 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • United States (By Product, and By Application)
      • Canada (By Product, and By Application)
      • Mexico (By Product, and By Application)
    • 5.3.2 Europe
      • Germany (By Product, and By Application)
      • United Kingdom (By Product, and By Application)
      • France (By Product, and By Application)
      • Italy (By Product, and By Application)
      • Spain (By Product, and By Application)
      • Rest of Europe (By Product, and By Application)
    • 5.3.3 Asia-Pacific
      • China (By Product, and By Application)
      • Japan (By Product, and By Application)
      • India (By Product, and By Application)
      • Australia (By Product, and By Application)
      • South Korea (By Product, and By Application)
      • Rest of Asia-Pacific (By Product, and By Application)
    • 5.3.4 Middle East and Africa
      • GCC (By Product, and By Application)
      • South Africa (By Product, and By Application)
      • Rest of Middle East and Africa (By Product, and By Application)
    • 5.3.5 South America
      • Brazil (By Product, and By Application)
      • Argentina (By Product, and By Application)
      • Rest of South America (By Product, and By Application)


  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Amgen, Inc.
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 F. Hoffmann-La Roche AG
    • 6.1.5 GlaxoSmithKline PLC
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Merck & Co.
    • 6.1.8 Novo Nordisk A/S
    • 6.1.9 Pfizer Inc.
    • 6.1.10 Sanofi SA
    • 6.1.11 Bayer AG
    • 6.1.12 AstraZeneca Plc
    • 6.1.13 Regeneron Pharmaceuticals, Inc.
    • 6.1.14 Novartis AG
    • 6.1.15 Teva Pharmaceutical Industries Ltd.